• New drug development
In particular, patient screening and predictive biomarker studies in clinical trials of tumor immune-targeted drugs show that PDX efficacy evaluation results and clinical similarity reached 87% (CDX only 5%).
• Personalized Medicine:
PDX model can be used to conduct pharmacodynamic (PD) evaluation experiments for tumor patients, providing clinical drug references for personalized treatment.
• Molecular Marker development (Biomarker)
Drug reactions -- Molecular biological mechanisms